左西孟坦联合血液净化治疗难治性心力衰竭的效果

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (35 KB)
Export: BibTeX | EndNote (RIS)

Abstract ObjectiveTo explore the effect of Levosimendan associated with blood purification in the treatment of refractory heart failure.Methods80 patients with refractory heart failure who were treated in EICU of our hospital from July 2015 to February 2017 were selected and divided into the control group and the treatment group according to the method of odd and even random grouping,40 cases in each group.The control group was given Dobutamine Torasemide and (or)Furosemide on the basis of conventional heart failure drugs.The treatment group was treated with Levosimendan and blood purification on the basis of routine drugs treatment for heart failure.The level of leftventricular ejection fraction(LVEF),cardiac output index (CI)and NT-proBNP were compared before and after treatment between the two groups.ResultsThe total effective rate after treatment in the treatment group was significantly higher than that in the control group,with significant difference (P＜0.05),the level of LVEF and CI after treatment in the treatment group was significantly higher than that in the control group,the level of NT-proBNP after treatment in the treatment group was lower than that in the control group,with significant difference(P＜0.05).ConclusionThe effect of Levosimendan associated with blood purification in the treatment of refractory heart failure is significant,which is worth applying in clinical.

Key words： Refractory heart failure Levosimendan associated with blood purification Therapy

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	XIAO Shi-hui
	LIU Qing-hong

Cite this article:

XIAO Shi-hui,LIU Qing-hong. Effect of Levosimendan associated with blood purification in the treatment of refractory heart failure[J]. 中国当代医药, 2017, 24(34): 40-42.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2017/V24/I34/40

[1]	中华医学会心血管病学分会，中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南[J].中华心血管病杂志，2014，42（2）：98-122.
[2]	Torbricki A，Perrier A，Konstantinides S，et al.Guidelines on the diagnosis and management of acute pulmonary embolism：the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology（ESC）[J].Eur Heart J，2008，29（18）：2276-2315.
[3]	于普林.老年医学[M].北京：人民卫生出版社，2002：86.
[4]	樊燕琴，杨清，吕继辉，等.高龄老年心力衰竭患者的临床特点分析[J].心肺血管病杂志，2015，34（6）：444-451.
[5]	甄宇治，邓彦东，刘坤申.慢性心力衰竭伴利尿剂抵抗的研究进展[J].中国全科医学，2012，15（11）：1290-1292.
[6]	张巨发，朱燕妮.连续低效每日透析滤过治疗顽固性心力衰竭合并肾功能不全的临床疗效观察[J].中国全科医学，2012， 15（20）：2347-2349.
[7]	温德良，刘卫江，古英明，等.连续性血液净化治疗重症心力衰竭合并肾衰竭患者的疗效分析[J].中国血液净化，2008，7（5）：260-262.
[8]	龙秀兰，任继刚，汪克纯，等.左西孟坦治疗难治性心力衰竭的疗效分析[J].现代实用医学，2014，26（8）：944-945.
[9]	贾志.左西孟坦在失代偿心力衰竭中应用的循证医学[J].吉林医学，2012，33（17）：3746-3747.
[10]	Cleland JG，Nilitin N，Mcgowan J.Levosimendan：first in a new class of inodilator for acute and chronic severe heart failure[J]Expert Rev Cardiovasc Ther，2004，2（1）：9-19.
[11]	Paraskevaidis IA，Parissis JT，Th Krenmstinos D.Anti-inflammatory and anti-apapteric effects of levosimendan in decomensated heart failure：a novel mechanism of drug-induced improvement in comtractile performance of the failing heart[J].Curr Med Chem Cardiovasc Hematol Agents，2005，3（3）：243-247.
[12]	Kyrzopeulos S，Adamopoulos S，Pariasis JT，et al.LevosimendanreducesplasmaB-typenatriureticpeptideandinterleukin 6，and improves central hemodynamics in severe heart failure patients[J].Int J Cardiol，2005，99（3）：409-413.
[13]	Avgeropoulou C，Andreadou I，Markantonis-Kyroudis S，et al.The Ca2+zensitizer levosimendan improves oxidative damage，BNP and pro-inflammatory cytokine level in patients with advanced decompensated heart failure in comparison to dobutamine[J].Eur J Heart Fail，2005，7（5）：882-887.
[14]	郭拥军，张登庆，葛艳，等.左西孟旦对慢性心力衰竭心室收缩同步性的影响[J]临床心血管病学杂志，2011，29（4）：254-256.
[15]	Fedele F，Bruno N，Brasolin B，et al.Levosimedan improves renal function in acute decompensated heart failure：possible underlying mechanisms[J].Eur J Heart Fail，2014，16（3）：281-284.